Transcriptome Profiling of Circulating Tumor Cells to Predict Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer DOI Open Access
Levi Groen, Iris S. H. Kloots, David Englert

et al.

International Journal of Molecular Sciences, Journal Year: 2023, Volume and Issue: 24(10), P. 9002 - 9002

Published: May 19, 2023

The clinical utility of circulating tumor cells (CTC) as a non-invasive multipurpose biomarker is broadly recognized. earliest methods for enriching CTCs from whole blood rely on antibody-based positive selection. prognostic CTC enumeration using selection with the FDA-approved CellSearchTM system has been demonstrated in numerous studies. capture specific protein phenotypes does not fully represent cancer heterogeneity and therefore realize potential liquid biopsies. To avoid this bias, enrichment based size deformability may provide better fidelity, i.e., facilitate characterization any phenotype. In study, recently Parsortix® technology was used to enrich prostate (PCa) patients transcriptome analysis HyCEADTM technology. A tailored PCa gene panel allowed us stratify metastatic castration-resistant (mCRPC) outcomes. addition, our findings suggest that targeted profiling be predictive therapy response.

Language: Английский

Lipid nanoparticles for targeted delivery of anticancer therapeutics: Recent advances in development of siRNA and lipoprotein-mimicking nanocarriers DOI Creative Commons
Anan Yaghmur, Jesper Østergaard, Huiling Mu

et al.

Advanced Drug Delivery Reviews, Journal Year: 2023, Volume and Issue: 203, P. 115136 - 115136

Published: Nov. 7, 2023

The limitations inherent in conventional cancer treatment methods have stimulated recent efforts towards the design of safe nanomedicines with high efficacy for combating through various promising approaches. A plethora nanoparticles has been introduced development nanomedicines. Among them, different lipid are attractive use due to numerous advantages and unique opportunities, including biocompatibility targeted drug delivery. However, a comprehensive understanding nano-bio interactions is imperative facilitate translation advancements into clinical practice. In this contribution, we focus on lipoprotein-mimicking nanoparticles, which possess features compositions facilitating transport receptor binding mechanisms. Additionally, describe potential applications siRNA future anticancer Thus, review highlights progress, challenges, opportunities lipid-based nanocarriers designed delivery therapeutic agents.

Language: Английский

Citations

18
Molecular Mechanisms of Cancer Drug Resistance: Emerging Biomarkers and Promising Targets to Overcome Tumor Progression DOI Open Access
Fabrizio Fontana, Martina Anselmi, Patrízia Limonta

et al.

Cancers, Journal Year: 2022, Volume and Issue: 14(7), P. 1614 - 1614

Published: March 23, 2022

Cancer still represents a major global burden, being the second leading cause of death worldwide [...].

Language: Английский

Citations

28
Prostate Cancer Stem Cells: Clinical Aspects and Targeted Therapies DOI Creative Commons
Isis Wolf, Christian Gratzke, Philipp Wolf

et al.

Frontiers in Oncology, Journal Year: 2022, Volume and Issue: 12

Published: July 8, 2022

Despite decades of research and successful improvements in diagnosis therapy, prostate cancer (PC) remains a major challenge. In recent years, it has become clear that PC stem cells (PCSCs) are the driving force tumorigenesis, relapse, metastasis, therapeutic resistance PC. this minireview, we discuss impact PCSCs clinical practice. Moreover, new approaches to combat presented with aim achieve an improved outcome for patients

Language: Английский

Citations

24
Aloe-emodin exhibits growth-suppressive effects on androgen-independent human prostate cancer DU145 cells via inhibiting the Wnt/β-catenin signaling pathway: an in vitro and in silico study DOI Creative Commons
Talib Hussain, Ahmed Alafnan, Ibrahim Abdullah Almazni

et al.

Frontiers in Pharmacology, Journal Year: 2024, Volume and Issue: 14

Published: Jan. 29, 2024

At the molecular level, several developmental signaling pathways, such as Wnt/β-catenin, have been associated with initiation and subsequent progression of prostate carcinomas. The present report elucidated anti-cancerous attributes an anthraquinone, aloe-emodin (AE), against androgen-independent human cancer DU145 cells. cytotoxicity profiling AE showed that it exerted significant cytotoxic effects increased lactose dehydrogenase levels in cells (

Language: Английский

Citations

5
How gallic acid regulates molecular signaling: role in cancer drug resistance DOI

Samira Hassani,

Fahimeh Ghanbari, Marzieh Lotfi

et al.

Medical Oncology, Journal Year: 2023, Volume and Issue: 40(11)

Published: Sept. 27, 2023

Language: Английский

Citations

12
Novel estrogen receptor β/histone deacetylase dual-targeted near-infrared fluorescent probes as theranostic agents for imaging and treatment of prostate cancer DOI
Pei He,

Huiguang Yu,

Xiaofei Deng

et al.

European Journal of Medicinal Chemistry, Journal Year: 2024, Volume and Issue: 268, P. 116236 - 116236

Published: Feb. 13, 2024

Language: Английский

Citations

4
Castration-resistant prostate cancer monitoring by cell-free circulating biomarkers DOI Creative Commons

Eva Chrenková,

Hana Študentová, Kateřina Holá

et al.

Frontiers in Oncology, Journal Year: 2024, Volume and Issue: 14

Published: Sept. 10, 2024

Prostate cancer is the second leading cause of male cancer-related deaths in Western countries, which predominantly attributed to metastatic castration-resistant stage disease (CRPC). There an urgent need for better prognostic and predictive biomarkers, particularly androgen receptor targeted agents taxanes.

Language: Английский

Citations

4
AR-V7 condensates drive androgen-independent transcription in castration resistant prostate cancer DOI Open Access
Shabnam Massah,

Nicholas Pinette,

Jane Foo

et al.

bioRxiv (Cold Spring Harbor Laboratory), Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 13, 2025

Summary Biomolecular condensates organize cellular environments and regulate key processes such as transcription. We previously showed that full-length androgen receptor (AR-FL), a major oncogenic driver in prostate cancer (PCa), forms nuclear upon stimulation androgen-sensitive PCa cells. Disrupting these impairs AR-FL transcriptional activity, highlighting their functional importance. However, resistance to deprivation therapy often leads castration-resistant (CRPC), driven by constitutively active splice variants like AR variant 7 (AR-V7). The mechanisms underlying AR-V7’s role CRPC remain unclear. In this study, we characterized the condensate-forming ability of AR-V7 compared its phase behavior with across spectrum models vitro conditions. Our findings indicate context can influence capacity. Unlike AR-FL, spontaneously absence functions independently models. requires higher concentration form condensates, both contexts . further reveal drives transcription via condensate-dependent condensate-independent mechanisms. Using an mutant incapable forming while retaining localization DNA-binding ability, regime activates part KRAS pathway Genes under were found harbor significantly numbers AR-binding sites exhibited boosted expression response AR-V7. These uncover unrecognized condensate formation driving programs shed light on unique contribution progression. Highlights androgens mediates independent Condensate-dependent enables genes exhibit exponential increase expression, number binding potentially playing reliance formation. Graphical Abstract

Language: Английский

Citations

0
The interplay of p16INK4a and non-coding RNAs: bridging cellular senescence, aging, and cancer DOI
Ashok Kumar Balaraman, Muhammad Afzal, Ehssan Moglad

et al.

Biogerontology, Journal Year: 2025, Volume and Issue: 26(2)

Published: Feb. 5, 2025

Language: Английский

Citations

0
Overcoming drug resistance in castrate-resistant prostate cancer: current mechanisms and emerging therapeutic approaches DOI Open Access
Adam Khorasanchi, Feng Hong, Yuanquan Yang

et al.

Cancer Drug Resistance, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 19, 2025

Metastatic castration-resistant prostate cancer (mCRPC) is driven by a complex network of resistance mechanisms against standard-of-care therapies, resulting in poor long-term outcomes. This review offers uniquely comprehensive and integrative perspective on these pathways, systematically examining both androgen receptor (AR)-dependent factors (including AR overexpression, point mutations, glucocorticoid signaling, splice variants, post-translational modifications, altered coregulators, intratumoral hormone biosynthesis) AR-independent pathways (such as neuroendocrine differentiation, lineage plasticity, alternative growth factor signaling). We also highlight influencing immunotherapy, chemotherapy, radiopharmaceutical therapy targeted therapy. By synthesizing emerging insights across domains, this not only clarifies the underlying biology mCRPC but identifies key leverage points for more effective interventions. Building foundation, we propose forward-looking framework overcoming drug resistance, emphasizing importance biomarker-guided patient selection, combination strategies that simultaneously target multiple mechanisms, novel therapies under investigation. These recommendations are intended to guide future clinical trial designs research priorities move beyond incremental improvements. Ultimately, synthesis aims serve resource clinicians researchers accelerate development durable, precision-based treatment mCRPC.

Language: Английский

Citations

0